Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II Clinical Trial.
This study is currently recruiting participants.
Verified September 2013 by Grupo Español de Investigación en Neurooncología
Study NCT01520870   Information provided by Grupo Español de Investigación en Neurooncología

First Received on January 18, 2012.   Last Updated on September 12, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Additional conditions recognized in this trial
More general conditions related to this trial
Interventions listed in this trial
Sponsors listed in this trial